← Comparing 2 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
TBK1 Loss Triggers eIF2α-Mediated Translational Repression T (TBK1, EIF2S1) — 0.00 eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote (EIF2S1,eIF2α,PERK,GCN2,ATF4,TOMM20,TIMM23,NDUFS1,NDUFS3,COX4I1,COX5A,mitochondrial protein import) — 0.00 TBK1 Loss Triggers Astrocyte-to-Neuron Senescence Propagatio (TBK1 → NF-κB / IRF3 / p62-autophagy / SASP effectors) — 0.00 GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl (GRIN2B) — 0.96 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.96 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.95 Plasma NfL Elevation Secondary to BBB-Associated Transport D (NEFL) — 0.94 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming (NLRP3, CASP1, IL1B, PYCARD) — 0.91 Gamma entrainment therapy to restore hippocampal-cortical sy (SST) — 0.90 Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla (SLC16A1, SLC16A7, LDHA, PDHA1) — 0.89 SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc (SIRT1) — 0.89 TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener (TREM2) — 0.89 Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Pa (APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis)) — 0.89 Optimized Temporal Window for Metabolic Boosting Therapy Det (IFNG) — 0.89 TREM2-APOE Axis Dissociation for Selective DAM Activation (TREM2-APOE axis) — 0.89 p38α Inhibitor and PRMT1 Activator Combination to Restore Ph (MAPK14/PRMT1) — 0.88 APOE-Dependent Autophagy Restoration (MTOR) — 0.88 Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 (BDNF) — 0.87 ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro (ACSL4) — 0.87 Complement Cascade Inhibition Synaptic Protection (%s) — 0.87 eIF2α Phosphorylation Imbalance Creates Integrated Stress Re (EIF2S1,eIF2α,PERK,GCN2,ATF4,ATF5,CHOP,DDIT3,integrated stress response,protein synthesis) — 0.87 Optogenetic restoration of hippocampal gamma oscillations vi (PVALB) — 0.87 Gamma Oscillation Entrainment Enhances lncRNA-9969-Mediated (PVALB, CREB1, lncRNA-9969, neuronal autophagy pathway) — 0.87 Glymphatic-Mediated Tau Clearance Dysfunction (MAPT) — 0.86 Closed-loop focused ultrasound targeting EC-II PV interneuro (PVALB) — 0.86 TREM2 R47H Variant-Driven Metabolic Dysfunction as the Prima (NAMPT) — 0.86 TREM2-Mediated Microglial Dysfunction Disrupts Perivascular (TREM2) — 0.86 Circadian Glymphatic Entrainment via Targeted Orexin Recepto (HCRTR1/HCRTR2) — 0.86 RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P (RBM45,GSK3B,TDP-43,TARDBP,hnRNP A1,HNRNPA1,phase separation,Liquid droplet) — 0.86
Add
|
× CX3CR1 Promoter Methylati × Optogenetic Microglial De
CX3CR1 · developmental neurobiology · -
Composite 0.649
Price $0.66
Evidence For 0
Evidence Against 0
## **Molecular Mechanism and Rationale**
The CX3CR1-mediated fractalkine signaling pathway represents a critical regulatory axis controlling neuron-microglia communication throughout development and aging. CX3CR1 (C-X3-C motif chemokine receptor 1) functions as the sole receptor for fractalkine (CX3CL1), a unique membrane-bound chemokine expressed constitutively on neurons. Under physiological conditions, fractalkine acts as a molecular "keep-off" signal, binding to microglial CX3CR1 to maintai
CX3CR1 · neurodegeneration · mechanistic
Composite 0.655
Price $0.70
Evidence For 0
Evidence Against 0
## Mechanistic Overview
Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins starts from the claim that modulating CX3CR1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The optogenetic microglial deactivation strategy exploits the selective expression of inhibitory opsins in microglia through CX3CR1-targeted delivery systems to achieve precise temporal and spatial cont
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
CX3CR1 Neuroinflammation
Convergent signals
CX3CR1 recurs across 2 selected hypotheses with aligned directionality in neuroinflammation.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary 7/11
dimensions won
CX3CR1 Promoter Methylation Disrupts Neu
4/11
dimensions won
Optogenetic Microglial Deactivation via
Radar Chart — 10 Dimensions
Score Breakdown
Dimension CX3CR1 Promoter Methylation Di Optogenetic Microglial Deactiv Mechanistic 0.750 0.500 Evidence 0.720 0.400 Novelty 0.650 0.950 Feasibility 0.700 0.150 Impact 0.580 0.650 Druggability 0.520 0.200 Safety 0.600 0.250 Competition 0.550 0.900 Data 0.680 0.350 Reproducible 0.650 0.300 KG Connect 0.500 0.793
Evidence CX3CR1 Promoter Methylation Disrupts Neuron-Microglia Cross- No evidence citations yet
Optogenetic Microglial Deactivation via Engineered Inhibitor No evidence citations yet
Debate Excerpts CX3CR1 Promoter Methylation Disrupts Neuron-Microg 4 rounds · quality: 0.71
Theorist # Mechanistic Hypotheses: Perinatal Immune Priming and Alzheimer's Disease
## Hypothesis 1: TREM2 Promoter Silencing via DNA Hypermethylation
**Mechanism:** Maternal immune activation (MIA) during c...
Skeptic # Critical Evaluation of Perinatal Immune Priming Hypotheses in Alzheimer's Disease
## Overview
These hypotheses propose mechanistic links between perinatal immune activation (MIA) and late-onset Al...
Domain Expert # Feasibility Assessment: Perinatal Immune Priming Hypotheses in Alzheimer's Disease
## Executive Summary
The seven mechanistic hypotheses proposing developmental origins for Alzheimer's disease via...
Synthesizer {
"ranked_hypotheses": [
{
"title": "CX3CR1 Promoter Methylation Disrupts Neuron-Microglia Cross-Talk",
"description": "Perinatal cytokines (IL-6) induce lasting CpG methylation at t...
Optogenetic Microglial Deactivation via Engineered 4 rounds · quality: 0.95
Theorist # Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease
## Hypothesis 1: Complement C1q Mimetic Decoy Therapy
**Description:** Engineer synthetic C1q mimetics that bind to sy...
Theorist # Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease
## Hypothesis 1: Complement C1q Mimetic Decoy Therapy
**Description:** Engineer synthetic C1q mimetics that bind to sy...
Skeptic # Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses
## Hypothesis 1: Complement C1q Mimetic Decoy Therapy
**Specific Weaknesses:**
- **Selectivity Problem:** C1q has essential physiolog...
Skeptic # Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses
## Hypothesis 1: Complement C1q Mimetic Decoy Therapy
**Specific Weaknesses:**
- **Selectivity Problem:** C1q has essential physiolog...
Price History Overlay
Knowledge Graph Comparison
CX3CR1 Promoter Methylation Disrupts Neu
0 edges
Top Node Types
Top Relations
Optogenetic Microglial Deactivation via
74 edges
Top Node Types gene 63
hypothesis 7
pathway 2
process 2
Top Relations co_discussed 38
co_associated_with 13
implicated_in 7
participates_in 4
associated_with 3